OverviewSuggest Edit

Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Listed on London’s AIM since 2005 (AIM: SLN), and with operations in London and Berlin, Silence is one of very few listed companies globally with human validated RNA delivery systems. Its AtuRNAi® technology is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. It has been used in three Phase 2 clinical trials, two awaiting results. Delivery capability is key for the next stage in genetic medicine, targeting disease right at the cause. Silence has an expanding early stage pipeline and collaborates with world leading research institutions to develop the most promising drug candidates. For more information, visit us at www.silence-therapeutics.com, or follow us on Twitter - @SilenceTheraPlc
TypePublic
Founded1999
HQLondon, GB
Websitesilence-therapeutics.com

Latest Updates

Employees (est.) (Feb 2019)50
Revenue (FY, 2017)£16 K(-97%)
Share Price (Oct 2017)£2.4 (+3%)

Key People/Management at Silence Therapeutics

David Horn Solomon

David Horn Solomon

Chief Executive Officer
Iain Ross

Iain Ross

Non-Executive Chairman
James Ede-Golightly

James Ede-Golightly

Non-Executive Director
Alistair Gray

Alistair Gray

Non-Executive Director
Dave Lemus

Dave Lemus

Non-Executive Director
Steven Romano

Steven Romano

Non-Executive Director
Show more

Silence Therapeutics Office Locations

Silence Therapeutics has offices in London and Berlin
London, GB (HQ)
72 Hammersmith Rd
Berlin, DE
Robert-Rössle-Straße 10
Show all (2)

Silence Therapeutics Financials and Metrics

Silence Therapeutics Revenue

Silence Therapeutics's revenue was reported to be £16 k in FY, 2017
GBP

Net income (FY, 2018)

(18.4m)

EBITDA (FY, 2018)

(20.2m)

EBIT (FY, 2018)

(20.6m)

Market capitalization (27-Oct-2017)

157.9m

Closing stock price (27-Oct-2017)

2.4

Cash (31-Dec-2018)

21.5m
Silence Therapeutics's current market capitalization is £157.9 m.
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

210.1k1.4m959.0k138.0k1.2m1.3m159.0k509.0k1.9m4.0m2.2m1.7m2.4m693.6k163.0k117.0k15.0k770.0k16.0k

Revenue growth, %

(87%)

Cost of goods sold

986.1k1.8m1.7m3.0m3.0m2.5m2.5m3.0m1.7m1.7m3.2m4.8m6.7m5.1m5.8m3.4m3.4m

Gross profit

(1.5m)(1.7m)(2.0m)(2.4m)(1.3m)(1.7m)(1.5m)(1.1m)(1.2m)(796.0k)(4.5m)(3.4m)(3.5m)(2.7m)(3.2m)
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

6.7m5.2m3.7m10.5m11.4m9.1m7.2m5.1m2.6m9.1m8.8m10.2m3.4m1.1m3.6m3.7m8.9m15.9m16.9m51.9m39.0m42.7m21.5m

Accounts Receivable

210.1k29.0k838.0k879.0k159.0k168.0k201.0k692.0k164.9k598.0k35.9k2.0k375.0k1.6m810.0k

Inventories

82.0k27.4k

Current Assets

6.7m5.2m3.9m10.8m12.0m9.6m8.4m6.4m3.2m9.7m9.6m11.6m4.4m1.8m4.4m3.9m9.1m21.3m22.2m53.6m42.0m45.5m29.5m
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(965.5k)(1.8m)(1.6m)(2.1m)(1.9m)(2.2m)(1.5m)(2.3m)(2.8m)(3.6m)(3.8m)(5.1m)(7.4m)(7.5m)(8.8m)(5.7m)(26.3m)(9.0m)(11.1m)(6.6m)(8.4m)(1.6m)(18.4m)

Cash From Operating Activities

1.0m1.9m2.1m1.2m3.4m3.1m2.4m2.5m2.7m2.8m4.0m3.8m(7.0m)(4.6m)(10.6m)(5.1m)(4.9m)(6.8m)(9.5m)(8.3m)(10.1m)(9.6m)(16.8m)

Cash From Financing Activities

6.3m5.6k289.0k8.0m3.9m8.0m(95.0k)9.5m3.5m5.2m3.8k2.7m12.4m5.5m10.2m18.8m10.8m39.2m(101.0k)48.0k341.0k

Net Change in Cash

5.5m1.5m1.5m685.0k87.0k772.0k6.1m2.1m2.2m6.5m267.0k1.4m(7.0m)(2.2m)2.4m165.1k5.2m6.9m1.2m35.2m(14.8m)3.5m(21.2m)
GBPY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Silence Therapeutics Online and Social Media Presence

Embed Graph

Silence Therapeutics News and Updates

Global Antisense And RNAi Therapeutics Market offers in-depth visions into the key drivers and Market Growth By focusing on top Key Operating Vendors - Isis Pharmaceuticals, Alnylam Pharmaceuticals, Silence Therapeutics, Antisense Therapeutics, Santaris,

Global Antisense And RNAi Therapeutics Market Trends, Analysis by Regions, Type, Application, Market Drivers, Restraints Forecasts to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™

LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms the receipt of a notice of intention to grant for a new European …

Silence Therapeutics litigation: patisiran EU marketing authorisation imminent

LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery and development of novel RNA therapeutics, announces today an update on litigation matters.

Silence Therapeutics Frequently Asked Questions

  • When was Silence Therapeutics founded?

    Silence Therapeutics was founded in 1999.

  • Who are Silence Therapeutics key executives?

    Silence Therapeutics's key executives are David Horn Solomon, Iain Ross and James Ede-Golightly.

  • How many employees does Silence Therapeutics have?

    Silence Therapeutics has 50 employees.

  • Who are Silence Therapeutics competitors?

    Competitors of Silence Therapeutics include Applied BioCode, Healthmap and Abingdon Health.

  • Where is Silence Therapeutics headquarters?

    Silence Therapeutics headquarters is located at 72 Hammersmith Rd, London.

  • Where are Silence Therapeutics offices?

    Silence Therapeutics has offices in London and Berlin.

  • How many offices does Silence Therapeutics have?

    Silence Therapeutics has 2 offices.